Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Mol Pharm ; 13(9): 2891-6, 2016 09 06.
Artículo en Inglés | MEDLINE | ID: mdl-26655747

RESUMEN

Many long-acting delivery strategies for ocular indications rely on pH- and/or temperature-driven release of the therapeutic agent and degradation of the drug carrier. Yet, these physiological parameters are poorly characterized in ocular animal models. These strategies aim at reducing the frequency of dosing, which is of particular interest for the treatment of chronic disorders affecting the posterior segment of the eye, such as macular degeneration that warrants monthly or every other month intravitreal injections. We used anesthetized white New Zealand rabbits, Yucatan mini pigs, and cynomolgus monkeys to characterize pH and temperature in several vitreous locations and the central aqueous location. We also established post mortem pH changes in the vitreous. Our data showed regional and species differences, which need to be factored into strategies for developing biodegradable long-acting delivery systems.


Asunto(s)
Cuerpo Vítreo/metabolismo , Anestésicos/uso terapéutico , Animales , Haplorrinos , Concentración de Iones de Hidrógeno , Inyecciones Intravítreas/métodos , Macaca fascicularis , Masculino , Modelos Animales , Conejos , Porcinos , Temperatura
2.
Hum Gene Ther ; 23(9): 980-91, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22716662

RESUMEN

RetinoStat(®) is an equine infectious anemia virus-based lentiviral gene therapy vector that expresses the angiostatic proteins endostatin and angiostatin that is delivered via a subretinal injection for the treatment of the wet form of age-related macular degeneration. We initiated 6-month safety and biodistribution studies in two species; rhesus macaques and Dutch belted rabbits. After subretinal administration of RetinoStat the level of human endostatin and angiostatin proteins in the vitreous of treated rabbit eyes peaked at ∼1 month after dosing and remained elevated for the duration of the study. Regular ocular examinations revealed a mild to moderate transient ocular inflammation that resolved within 1 month of dosing in both species. There were no significant long-term changes in the electroretinograms or intraocular pressure measurements in either rabbits or macaques postdosing compared with the baseline reading in RetinoStat-treated eyes. Histological evaluation did not reveal any structural changes in the eye although there was an infiltration of mononuclear cells in the vitreous, retina, and choroid. No antibodies to any of the RetinoStat vector components or the transgenes could be detected in the serum from either species, and biodistribution analysis demonstrated that the RetinoStat vector was maintained within the ocular compartment. In summary, these studies found RetinoStat to be well tolerated, localized, and capable of persistent expression after subretinal delivery.


Asunto(s)
Terapia Genética/métodos , Vectores Genéticos , Virus de la Anemia Infecciosa Equina , Degeneración Macular/metabolismo , Degeneración Macular/terapia , Cuerpo Vítreo/metabolismo , Angiostatinas/biosíntesis , Angiostatinas/genética , Animales , Endostatinas/biosíntesis , Endostatinas/genética , Humanos , Leucocitos Mononucleares/metabolismo , Leucocitos Mononucleares/patología , Macaca mulatta , Degeneración Macular/patología , Conejos , Factores de Tiempo , Cuerpo Vítreo/patología , Cuerpo Vítreo/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...